Wishing you and your families a happy and safe holiday season! We will be back in January 2021 with new content. Hope you have a fantastic new year!
Hi everyone! This is a quick message from the volunteers behind SCAsource. We are super excited to announce that we have received our first external financial support, a £1,200 grant from Ataxia UK.
Ataxia UK is a charity organization located in the United Kingdom which supports people affected by any form of ataxia. This grant will help us with the operational costs of the website for the next two years, as well as help improve our visuals through images licences. We are incredibly grateful for this support. It is helping us begin the transition from a pilot project to a long-term sustainable initiative.
One important thing to note is that our funders do not have special access to SCAsource content, which is free for all to use and share through a Creative Commons Attribution-ShareAlike 3.0 Unported License. Ataxia UK does not have any editorial control over SCAsource articles and they are not responsible for any content published.
We wanted to share this exciting news with all of you! SCAsource will continue to seek out funding sources to ensure our website can continue to grow over the long term. We will be back next week with a new SCAsource Snapshot.
Today marks International Ataxia Awareness Day, which is celebrated every year on September 25th. IAAD brings people together from around the world to raise awareness about this group of rare diseases and to raise money for continuing research efforts.
Here at SCAsource, we are celebrating International Ataxia Awareness Day 2020 by highlighting our top ten most-read articles from this year. We hope you enjoy reading these throwbacks!
Basic biology helps identify a new treatment for ataxia. Work from groups in Michigan and California show in mice that not all medications that improve disease symptoms in the short term will continue to do so in the long term
In a tour de force study, a collaborative team of scientists led by Dr. Rudolph Tanzi (Harvard Medical School) and Dr. Huda Zhogbi (Baylor College of Medicine) found a novel relationship between the Spinocerebellar ataxia type 1 gene (ATXN1) and Alzheimer’s disease.
One drug to treat them all: an approach using RNA interference to selectively lower the amount of mutant protein in all polyglutamine diseases. Work by a group in Poland shows initial success in Huntington’s Disease, DRPLA, SCA3/MJD, and SCA7 patient cells.
Cholesterol to the rescue: An alternative approach to treating SCA type 3 using gene therapy.
A new therapeutic compound shows promise to treat Friedrich’s Ataxia. But what exactly does Omaveloxolone do in the body? What next steps are being taken to test it?
Collaboration between researchers in Portugal and the United Kingdom discovers that a canola oil by-product shows promise, corrects MJD/SCA3 and Parkinson’s Disease symptoms in animal models.
The CRISPR gene-editing toolbox expanded with the addition of prime editing. Prime editing has astounding potential for both basic biology research and for treating genetic diseases by theoretically correcting ~89% of known disease-causing mutations.
3. Two or more birds with one stone: Designing a single therapeutic strategy to treat multiple types of spinocerebellar ataxia
A newly-proposed treatment strategy might be effective against several forms of spinocerebellar ataxia and other CAG repeat-associated disorders
Researchers from the University of California show they can “edit” the Frataxin gene in human cells from Friedreich’s Ataxia and transplant them into mice. This lays the groundwork for this method to be tested for safety.
A research group in Michigan report the creation of the first NIH-approved human cell model that mirrors SCA3 disease features – cellular defects that, after gene therapy, show improvement
Hi everyone! This is a quick message from the volunteers behind SCAsource. About a year ago we conducted a feedback study to ask what we were doing well and what we could change or improve. Some of the changes we hoped to introduce back in the spring were delayed due to COVID-19.
But we are so excited to introduce to you one of the changes we are making! We are adding a new article type: SCAsource Spotlights.
One of the things you told us you wanted to know more about was who is doing ataxia research. What labs exist? Where are they located? What questions are they asking? Who are these researchers?
SCAsource Spotlights will be able to shed some light on this. They will be short profiles of ataxia laboratories around the world. In addition to what science is going on in these labs, each Spotlight will also include a fun fact about something that makes that research group unique.
Please let us know how you like this new article type! Our first Spotlight will be on the Watt Lab from McGill University in Montreal, Canada!
If you are from an ataxia lab and want us to do a Spotlight on you, please get in touch with us through our contact page.
Today marks Rare Disease Day, which aims to raise awareness for the 300 million people around the world who live with rare diseases. Spinocerebellar ataxia, Friedreich’s Ataxia, and ARSACS are just a few of the of over 6000 rare diseases that have been identified.
The main goal of raising awareness of Rare Disease Day is to achieve equity for people living with rare diseases. By their nature, people living with rare diseases can run into a number of barriers in health care systems designed for common diseases. This includes access to diagnosis, ongoing care, and treatment. Folks can also face discrimination when attending school or at work.
Today is a call to action for people with rare diseases to have equal opportunities in work and social life, as well as access to health care and treatment.
For more information, including milestones in achieving equity, actions you can take to advocate for equity, and a list of events occurring worldwide, visit RareDiseaseDay.org.